Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + sitagliptin adjuvant study in muscle-invasive urothelial carcinoma
ChiCTR2500102460Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and sitagliptin in transitional cell carcinoma (TCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: dose-limiting toxicity and 2-year disease-free survival rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
nivolumabsitagliptin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2500102460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102460.